RTNXF News and Press, Renalytix AI PLC From 12/08/21

Renalytix Plc (RNLX) Q1 2022 Earnings Conference Call December 7, 2021 8:30 AM ET Company Participants Peter Denardo – CapComm Partners James Mccullough – Chief Executive Officer Thomas Mclain – President James Sterling – Chief Financial Officer Conference Call Par...

Renalytix Plc (RNLX) Q4 2021 Earnings Conference Call October 21, 2021 8:30 A.M. ET Company Participants Peter DeNardo - CapComm Partners James McCullough - Chief Executive Officer Tom McLain - President James Sterling - Chief Financial Officer Conference Call Participants Dan Macek - Stifel ...

Renalytix's earnings call on Thursday could move the stock, especially if there is good news on sales to new health system clients. The conceptual sell for the company's platform is growing and I expect 2022 to 2023 to be transformative. Valuation remains difficult due to miniscul...

Renalytix AI plc (RNLX) Q3 2021 Earnings Conference Call June 15, 2021 08:30 ET Company Participants Carrie Mendivil - Investor Relations James McCullough - Co-Founder and Chief Executive Officer Tom McLain - President James Sterling - Chief Financial Officer Conference Call Participants Dan ...

Renalytix AI continues to soar. The story of AI-enhanced kidney diagnostics is attractive, albeit the addressable market isn't huge. But the company is basically in an early stage, with zero revenue. I don't see a sound financial justification for the current valuation. For ...

Teva receives tentative FDA nod for generic idiopathic pulmonary fibrosis treatment Teva Pharmaceutical Industries ( TEVA ) received tentative approval from the FDA for generic pirfenidone. The drug candidate is aimed towards treating idiopathic pulmonary fibrosis. The tentative approval i...